Article

Where goeth the 110th Congress?

Any major changes in health care will reflect the inflluence of moderates on both sides of the aisle.

In general, and in simple terms, Republican health policy has favored large insurers, managed care, and pharmaceutical companies, and it has limited public program spending and lowered product and medical liability. Democrats distrust private approaches to health care, including Medicare HMOs (a.k.a. Medicare Advantage), and support Medicare fee-for-service (FFS) and the expansion of benefits for preventive care under public programs, such as expanding Medicare pharmacy benefits while limiting increases in beneficiary payments.

This will mark the end of massive support of Medicare Advantage plans, which currently are paid 11% more than FFS health savings accounts.

Because Sen. Max Baucus (D-MT) and Sen. Charles E. Grassley (R- IA) have a similar moderate approach with rural health care as a priority, no big change in emphasis is expected in the Senate.

Probably the biggest benefit for the profession is an effect of the distrust Democratic policymakers have for Medicare Advantage. This distrust will benefit ophthalmologists because Medicare HMOs typically pay 25% less for covered physician services than Medicare FFS. From a policy perspective, Republicans have had no burning desire to fix the problems with the sustainable growth rate (SGR) in Medicare FFS, which leads to yearly entreaties to Congress (accompanied by lobbying dollars) for temporary fixes or freezes in payment.

Anything that would benefit Medicare FFS is not consistent with Republican policy of disincentives for physician and beneficiary interest in Medicare FFS. Democrats want to preserve Medicare FFS, but it must be remembered their primary concern is the beneficiary; physicians will benefit only secondarily as a result of the Democrats' strong desire to maintain the popular Medicare programs.

Long-range outlook

What does this portend for our profession? I doubt there will be any long-term fix to the SGR, because the 10-year cost is more than $220 billion.

There may be more support for the MedPac policy wanting to eliminate the SGR, raise the conversion factor 2% in Medicare FFS, and implement widespread physician payment reform that would help stabilize the Medicare FFS program for beneficiaries. While the design of a new payment mechanism along the lines of pay for performance is evaluated, there may be some support for a 2-year fix.

Reauthorization and expansion of the State Children's Health Insurance Program (SCHIP) will be a Democratic priority. This emphasis on expanding services for children may lead to some action on the Vision Care Kids Act (S. 3685 and H.R. 6227).

After years of negotiations, the American Optometric Association, the American Academy of Ophthalmology (AAO), and the Vision Council of America have reached a consensus that would complement state programs-by providing funding in the form of state grants for eye examinations and additional treatment for uninsured children with eye problems.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.